CARDIOVASCULAR MEDICINE

Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies

U Wetzel¹, A Boldt¹, J Lauschke¹, J Weigl¹, P Schirdewahn¹, A Dorszewski¹, N Doll², G Hindricks¹, S Dhein², H Kottkamp¹

¹ Department of Electrophysiology, University of Leipzig Heart Centre, Leipzig, Germany
² Department of Cardiovascular Surgery, University of Leipzig Heart Centre

Correspondence to:
Correspondence to:
Dr Ulrike Wetzel
Department of Electrophysiology, Cardiology, University of Leipzig Heart Centre, Strümpellstrasse 39, D-04289 Leipzig, Germany; ulrike_wetzel{at}hotmail.com

Objective: To test the hypothesis that atrial fibrillation (AF) is associated with changes in the expression of connexins 40 and 43 in the left atrium with more pronounced changes in mitral valve disease than in lone AF.

Methods: Protein concentrations of connexin 40 and connexin 43 were analysed in left atrial tissue of patients undergoing cardiac surgery. One group of patients had lone AF (n = 41), one group had AF and mitral valve repair (n = 36), and one group in sinus rhythm served as controls (n = 15).

Results: Western blot analysis of connexin 40 and connexin 43 expression showed an increase of both gap junctional proteins (connexin 43 > connexin 40) in patients with AF of all forms compared with patients in sinus rhythm (p = 0.01 and p = 0.011, respectively). Subgroup analysis showed increased concentrations of connexin 40 in lone AF and AF with mitral valve disease compared with sinus rhythm (p = 0.06 and p = 0.029, respectively), whereas the same analysis for connexin 43 reached significance only in the mitral valve disease group (p = 0.031). No differences in connexin 40 and connexin 43 expression were detectable between lone AF and AF with mitral valve disease. Within the groups connexin 40 and connexin 43 expression did not differ between patients with paroxysmal AF and patients with chronic AF.

Conclusion: The present study shows for the first time that AF can induce changes in the left atrium with increased connexin expression. Furthermore, no systematic differences between patients with paroxysmal and chronic AF were detected.

Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAF, chronic atrial fibrillation; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HEPES, hydroxyethylpiperazine-ethanesulfonic acid; MVD, mitral valve disease; PAF, paroxysmal atrial fibrillation; SR, sinus rhythm

Keywords: atrial fibrillation; connexin; gap junctions; human atrium

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Chaldoupi, S.-M., Loh, P., Hauer, R. N.W., de Bakker, J. M.T., van Rijen, H. V.M. (2009). The role of connexin40 in atrial fibrillation. Cardiovasc Res 84: 15-23 [Abstract] [Full Text]  
• Rossman, E. I., Liu, K., Morgan, G. A., Swillo, R. E., Krueger, J. A., Gardell, S. J., Butera, J., Gruver, M., Kantrowitz, J., Feldman, H. S., Petersen, J. S., Haugan, K., Hennan, J. K. (2009). The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model. J. Pharmacol. Exp. Ther. 329: 1127-1133 [Abstract] [Full Text]  
• Almeida, N. A. S., Cordeiro, A., Machado, D. S., Souza, L. L., Ortiga-Carvalho, T. M., Campos-de-Carvalho, A. C., Wondisford, F. E., Pazos-Moura, C. C. (2009). Connexin40 Messenger Ribonucleic Acid Is Positively Regulated by Thyroid Hormone (TH) Acting in Cardiac Atria via the TH Receptor. Endocrinology 150: 546-554 [Abstract] [Full Text]  
• Savelieva, I., Camm, J. (2008). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10: 647-665 [Abstract] [Full Text]  
• Nattel, S., Burstein, B., Dobrev, D. (2008). Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications. Circ Arrhythm Electrophysiol 1: 62-73 [Full Text]  
• Burstein, B., Nattel, S. (2008). Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation. J Am Coll Cardiol 51: 802-809 [Abstract] [Full Text]  
• Sarrazin, J.-F., Comeau, G., Daleau, P., Kingma, J., Plante, I., Fournier, D., Molin, F. (2007). Reduced Incidence of Vagally Induced Atrial Fibrillation and Expression Levels of Connexins by n-3 Polyunsaturated Fatty Acids in Dogs. J Am Coll Cardiol 50: 1505-1512 [Abstract] [Full Text]  
• Nattel, S., Maguy, A., Le Bouter, S., Yeh, Y.-H. (2007). Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation. Physiol. Rev. 87: 425-456 [Abstract] [Full Text]  
• Rucker-Martin, C., Milliez, P., Tan, S., Decrouy, X., Recouvreur, M., Vranckx, R., Delcayre, C., Renaud, J.-F., Dunia, I., Segretain, D., Hatem, S. N. (2006). Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res 72: 69-79 [Abstract] [Full Text]  
• Guerra, J. M., Everett, T. H. IV, Lee, K. W., Wilson, E., Olgin, J. E. (2006). Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation. Circulation 114: 110-118 [Abstract] [Full Text]